Combination therapy with CD47 blockade and anti-angiogenic drugs produces significant tumor inhibition activity in bladder cancer, which could be explained by the control or normalization of angiogenesis, as well as the further increment of tumor-infiltrating macrophages and pro-inflammatory cytokine production (Figure 6). This evidence concerns the gene CD47 and urinary bladder cancer.